ArticleThe Kaohsiung journal of medical sciences2026
Allogeneic Human Bone Marrow-Derived Mesenchymal Stem Cells Accelerate Diabetic Wound Healing via Inflammation Suppression and Angiogenesis Promotion: A Preclinical Study.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mesenchymal stem cells (MSCs) have been shown to enhance tissue regeneration and wound healing. This preclinical study investigated the therapeutic potential of human bone marrow-derived mesenchymal stem cells (hBM-MSCs) for accelerating diabetic wound healing. Isolated hBM-MSCs were characterized for surface marker expression and differentiation potential. Their migration-promoting effects were evaluated in vitro. For the in vivo study, a dorsal skin defect model was created in streptozotocin (STZ)-induced diabetic rats. Rats received periwound subcutaneous injections of low- or high-dose hBM-MSCs on Days 4 and 7, or freezing fluid as a vehicle control. Wound healing progression was assessed clinically, and tissue biopsies were analyzed using immunohistochemistry to evaluate inflammatory cell infiltration, cellular proliferation, and angiogenesis. hBM-MSCs exhibited the expected surface marker profile and multilineage differentiation potential. In vitro, hBM-MSCs significantly enhanced the migration of human umbilical vein endothelial cells and human foreskin fibroblasts. In vivo, wounds treated with hBM-MSCs showed significantly accelerated healing compared to vehicle-treated controls (p < 0.05). Immunohistochemical analysis revealed reduced inflammatory cell infiltration and increased expression of Ki-67, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and prolyl 4-hydroxylase (P4H) in hBM-MSC-treated wounds. Allogeneic hBM-MSCs significantly promote diabetic wound healing by suppressing inflammation, enhancing cellular proliferation and differentiation, and stimulating angiogenesis. These findings highlight the therapeutic potential of allogeneic hBM-MSCs for treating diabetic wounds, particularly in patients unsuitable for autologous cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.